2jenn / Shutterstock.com
Ahead of the English Court of Appeal’s hearing in May in the Warner-Lambert case on second medical use patents, Charlotte Weekes and Tamsin Cornwell of Pinsent Masons examine some of the unanswered questions.
Described by legal commentators as “the case of year”, and with numerous interim issues decided, English judge Mr Justice Arnold and the Court of Appeal have already grappled with a number of issues in Warner-Lambert (Pfizer) v Actavis and Mylan & Actavis v Warner-Lambert leading up to the decision of Arnold on September 10, 2015 on infringement and validity respectively.
Arnold found Warner-Lambert’s patent (EP 0 934 061), protecting the use of pregabalin for the treatment of pain, partially invalid for insufficiency and neither directly nor indirectly infringed by Actavis’s skinny label pregabalin product sold for epilepsy and generalised anxiety disorder.
Pfizer’s Lyrica is authorised for use in these conditions and neuropathic pain. Essentially there was held to be no foreseeability on the part of Actavis of the intentional use of Pfizer’s product for pain. Actavis also had taken a number of steps, including writing to Clinical Commissioning Groups and pharmacists, to prevent the use of its product in a potentially infringing manner. Furthermore, the National Health Service (NHS) guidance, which the court had ordered to be issued, would serve to prevent infringement, although Warner-Lambert disagreed.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Charlotte Weekes, Tamsin Cornwell, Pinsent Masons , Warner-Lambert v Sandoz, NHS, patent, Actavis, Pfizer,
